VKTX Quote, Financials, Valuation and Earnings

Amgen has a net margin of -- compared to Viking Therapeutics's net margin of 6.9%. Viking Therapeutics's return on equity of -- beat Amgen's return on equity of 66.87%.

Viking Therapeutics has a consensus price target of $99.29, signalling upside risk potential of 309.97%. On the other hand Amgen has an analysts' consensus of $316.10 which suggests that it could grow by 2.02%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

Viking Therapeutics has a beta of 0.838, which suggesting that the stock is 16.205% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.95% to investors and pays a quarterly dividend of $2.38 per share. Viking Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Viking Therapeutics quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Viking Therapeutics's net income of -$35.4M is lower than Amgen's net income of $627M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 41.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 5.01x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Viking Therapeutics's net margin of 32.59%. Viking Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Viking Therapeutics has a consensus price target of $99.29, signalling upside risk potential of 309.97%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 28.06%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Viking Therapeutics has a beta of 0.838, which suggesting that the stock is 16.205% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.50 per share. Viking Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Viking Therapeutics's net income of -$35.4M is lower than Eli Lilly and's net income of $4.4B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 67.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 15.84x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Viking Therapeutics's net margin of 2.31%. Viking Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.91%.

Viking Therapeutics has a consensus price target of $99.29, signalling upside risk potential of 309.97%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 28.69%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

Viking Therapeutics has a beta of 0.838, which suggesting that the stock is 16.205% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.96% to investors and pays a quarterly dividend of $0.43 per share. Viking Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Viking Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Viking Therapeutics's net income of -$35.4M is lower than Pfizer's net income of $410M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 2.18x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -- compared to Viking Therapeutics's net margin of --. Viking Therapeutics's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

Viking Therapeutics has a consensus price target of $99.29, signalling upside risk potential of 309.97%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 718.13%. Given that Terns Pharmaceuticals has higher upside potential than Viking Therapeutics, analysts believe Terns Pharmaceuticals is more attractive than Viking Therapeutics.

Viking Therapeutics has a beta of 0.838, which suggesting that the stock is 16.205% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Viking Therapeutics quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Viking Therapeutics's net income of -$35.4M is lower than Terns Pharmaceuticals's net income of -$21.8M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.